Sino Biopharm, GSK in exclusive China pact for breakthrough hepatitis B drug

Sino Biopharmaceutical ( (HK:1177) ) just unveiled an announcement.

Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has entered an exclusive strategic collaboration with GSK to commercialise bepirovirsen for chronic hepatitis B in mainland China. CTTQ will handle importation, distribution and market access, recognise product revenue, and may expand the partnership into broader R&D collaborations, reinforcing Sino Biopharmaceutical’s role as a preferred partner for multinational drugmakers.

Bepirovirsen, a first-in-class antisense oligonucleotide granted Breakthrough Therapy status in China, is supported by positive Phase III data and aligns with national goals to achieve functional cure in hepatitis B. Leveraging CTTQ’s leading hepatitis B franchise and network of more than 5,000 medical centres, the deal is expected to accelerate patient access, enhance the company’s innovative pipeline and support future revenue growth in a large, unmet public health market.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical is a China-focused pharmaceutical group with a strong presence in hepatology through its subsidiary Chia Tai Tianqing Pharmaceutical Group. The company offers a comprehensive portfolio of liver disease treatments, has blockbuster hepatitis B drugs, and is advancing multiple innovative candidates targeting MASH, hepatitis B cure, liver cirrhosis and acute liver injury.

YTD Price Performance: -12.14%

Average Trading Volume: 70,341,278

Technical Sentiment Signal: Buy

Current Market Cap: HK$97.03B

For detailed information about 1177 stock, go to TipRanks’ Stock Analysis page.